A 48-year-old woman with bipolar I disorder has been stable on lithium 600 mg twice daily for 5 years. At her routine outpatient visit, serum lithium level is 1.1 mEq/L (therapeutic), but her serum creatinine has risen from baseline 0.9 mg/dL to 1.3 mg/dL over the past 18 months. Urinalysis shows no proteinuria. She denies polyuria or polydipsia. What is the most appropriate next step in management?

Explanation

## Lithium-Associated Chronic Kidney Disease: Monitoring & Management This patient shows **progressive renal dysfunction** (Cr rise from 0.9 to 1.3 mg/dL over 18 months) despite therapeutic lithium levels. This pattern is consistent with **lithium-induced chronic kidney disease (CKD)**, a known long-term complication requiring systematic evaluation. ### Key Point: **Lithium causes dose-dependent, often irreversible chronic kidney disease in 20–40% of long-term users. Progressive rise in serum creatinine mandates formal GFR assessment and nephrology evaluation, not empiric dose reduction or continuation.** ### Pathophysiology of Lithium Nephrotoxicity | Feature | Mechanism | |---------|----------| | **Acute phase** | Polyuria (nephrogenic diabetes insipidus–like), reversible | | **Chronic phase** | Interstitial fibrosis, glomerulosclerosis, tubular atrophy — often irreversible | | **Risk factors** | Duration >5 years, cumulative dose, episodes of toxicity, dehydration | | **Monitoring marker** | Rising serum creatinine or falling eGFR | ### High-Yield: **Lithium-induced CKD is dose-dependent but NOT always reversible. Early detection via GFR and renal imaging can guide intervention.** ### Recommended Monitoring Protocol ```mermaid flowchart TD A[Long-term lithium user with rising Cr]:::outcome --> B[Calculate eGFR/GFR]:::action B --> C{GFR status?}:::decision C -->|GFR ≥60| D[Renal ultrasound to assess structure]:::action C -->|GFR 30-59| E[Nephrology referral; consider dose reduction or switch]:::action C -->|GFR <30| F[URGENT: Nephrology referral; likely discontinue lithium]:::urgent D --> G{Ultrasound findings?}:::decision G -->|Normal| H[Continue lithium; monitor GFR q6-12 months]:::action G -->|Cystic changes/fibrosis| I[Nephrology referral; discuss risk-benefit of continuation]:::action E --> J[Recheck GFR in 3 months]:::action I --> J ``` ### Clinical Pearl: In this case: - Serum creatinine rose 44% over 18 months (0.9 → 1.3 mg/dL) - Lithium level is therapeutic (not toxic) - No proteinuria or polyuria symptoms reported **This pattern suggests early-to-moderate lithium-induced CKD.** The next step is **formal GFR calculation** (using CKD-EPI equation) and **renal imaging** to assess structural changes. If GFR is <60 mL/min/1.73m², nephrology referral is indicated to discuss dose adjustment, switch to an alternative mood stabilizer, or continuation with close monitoring. ### Mnemonic: LITHIUM NEPHROTOXICITY MANAGEMENT - **L**evel: Keep therapeutic (0.6–1.2 mEq/L) to minimize risk - **I**ncreased Cr: Triggers GFR calculation and imaging - **T**ime: Monitor GFR every 6–12 months on lithium - **H**ydration: Maintain adequate fluid intake (reduces concentration) - **I**maging: Renal ultrasound if GFR declining or Cr rising - **U**rinalysis: Screen for proteinuria (sign of glomerular disease) - **M**anagement: Nephrology referral if GFR <60 ### Why NOT Empiric Dose Reduction? Dose reduction without GFR data is premature and risks: - Inadequate mood stabilization (relapse risk) - Missing the opportunity to assess reversibility with imaging - Delaying specialist input if structural renal disease is present [cite:Kaplan & Sadock's Synopsis of Psychiatry 12e Ch 31; Kidney Disease: Improving Global Outcomes (KDIGO) 2021]